Clinical Efficacy of Osimertinib in Targeted Therapies of Patients with Non Small Cell Lung Cancer A Randomized Controlled Trial

OBJECTIVE: To explore the clinical efficacy of osimertinib in targeted therapies of patients with non-small cell lung cancer (NSCLC), thus providing experimental data for clinical treatment of this disease. STUDY DESIGN: A total of 120 patients with NSCLC who underwent treatment in our hospital between November 2020 and August 2021 were enrolled. These patients were divided randomly into platinumpemetrexed chemotherapy group (PP) (n=6) and osimertinib targeted therapy group (OT) (n=6). A CT scan was employed for examining patients before and after treatment, and the occurrence of adverse reactions was recorded. The levels of tumor-related markers in serum including carcinoembryonic antigen (CM), cytokeratin 19 fragment (CYFRA21-1), neuron-specific enolase (NSE), and carbohydrate antigen 125 (CA125) were compared before and after treatment. Flow cytometry was used to detect the proportion of CD3+, CD4+, and CD8+ T lymphocyte subsets in peripheral blood of patients. Kaplan-Meier method was used to calculate the survival of patients after treatment. RESULTS: There was no significant difference in the general data between the 2 groups. According to CT imaging, as compared with the PP group, tumor volume was decreased significantly in the OT group. After treatment, the tumor-related markers in the serum and adverse reactions in the OT group were significantly less than those of the PP group; also, the proportions of CD3+, CD4+, and CD8+ T lymphocytes were higher than those of the PP group. Compared with the PP group, the survival of patients after treatment was higher in the OT group. CONCLUSION: Osimertinib (a targeted therapy) shows better efficacy than platinum-pemetrexed (a chemotherapy) in the treatment of NSCLC and has a good therapeutic prospect.